Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.

Employees

Sector

Biotechnology & Medical Research

More about the company

17-08-27	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
17-08-10	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI

Market Cap	772M 669M 633M 573M 1.08B 74.1B 1.08B 7.55B 2.9B 37.57B 2.9B 2.84B 120B	P/E 2018	28.3x	P/E 2019	13.3x
Enterprise Value	689M 597M 565M 511M 959M 66.13B 967M 6.74B 2.59B 33.53B 2.59B 2.53B 107B	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	68.13%	Yield 2018 *	-	Yield 2019	-

17-08-27	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
17-08-10	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI
17-07-10	Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million	CI
15-11-28	Mertiva AB's Equity Buyback announced on December 6, 2012, has expired.	CI
14-12-17	Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million.	CI
14-01-21	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
13-10-11	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
13-10-08	The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B).	CI
13-09-25	Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million.	CI
13-08-27	Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index	CI
13-07-30	Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index	CI
13-07-04	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
13-04-22	Diamyd Medical AB Announces Board Appointments	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.56%	-4.17%	-1.90%	+9.79%	45.63B
REVOLUTION MEDICINES, INC.	-0.01%	-1.18%	+343.46%	+545.09%	43.96B
IQVIA HOLDINGS INC.	+1.43%	+4.37%	+45.47%	+27.78%	43.73B
BEONE MEDICINES AG	-2.22%	-1.29%	+4.42%	+73.20%	40.23B
CELLTRION, INC.	-0.73%	-4.72%	+8.55%	+37.89%	31.86B
ASCENDIS PHARMA A/S	-9.44%	-11.59%	-	-	17.4B
MEDPACE HOLDINGS, INC.	+4.10%	+5.26%	+25.30%	+122.16%	16.62B
EUROFINS SCIENTIFIC SE	+1.83%	+2.63%	+15.14%	+33.31%	14.46B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.21%	-2.52%	+79.78%	+31.66%	13.04B
Average	-0.43%	-1.81%	+65.03%	+110.11%	29.66B
Weighted average by Cap.	-0.28%	-2.09%	+76.67%	+131.06%

	2018	2019
Net sales	-	-
Net income	25.3M 21.91M 20.72M 18.76M 35.21M 2.43B 35.47M 247M 95.14M 1.23B 95.03M 92.92M 3.92B	76.99M 66.69M 63.06M 57.09M 107M 7.39B 108M 753M 290M 3.74B 289M 283M 11.94B
Net Debt	-253M -219M -207M -188M -352M -24.25B -355M -2.47B -951M -12.3B -950M -929M -39.22B	-83.08M -71.96M -68.05M -61.6M -116M -7.97B -116M -812M -312M -4.04B -312M -305M -12.89B

Diamyd Medical AB Stock Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation: Diamyd Medical AB

Latest news: Diamyd Medical AB

Other Biotechnology & Medical Research

Financials

Company Profile

End-of-day quote Nasdaq Stockholm
- ^SEK	-